Illumina (ILMN) Stock Price, News & Analysis

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.

19 Wall Street research analysts have issued 12 month price objectives for Illumina's stock. Their ILMN share price targets range from $80.00 to $258.00. On average, they expect the company's share price to reach $166.95 in the next year. This suggests a possible upside of 16.5% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.

Illumina's stock was trading at $139.24 at the start of the year. Since then, ILMN shares have increased by 2.9% and is now trading at $143.33.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our ILMN earnings forecast.

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings data on Thursday, November, 9th. The life sciences company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.13 by $0.20. The life sciences company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a positive trailing twelve-month return on equity of 2.13% and a negative net margin of 25.20%. The company's quarterly revenue was up .4% on a year-over-year basis. During the same quarter last year, the firm posted $0.34 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco Biotechnology & Genome ETF (PBE), VanEck Biotech ETF (BBH), Global X Telemedicine & Digital Health ETF (EDOC), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and Global X Genomics & Biotechnology ETF (GNOM).

Illumina issued an update on its fourth quarter 2023 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.32%), GUARDCAP ASSET MANAGEMENT Ltd (1.29%), Charles Schwab Investment Management Inc. (0.58%), Ownership Capital B.V. (0.51%), Nuance Investments LLC (0.45%) and Swiss National Bank (0.31%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jay T Flatley, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends.

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.